Advanced Pre-clinical Evaluation of the Guanidino Lipoglycopeptides: A Novel Family of Glycopeptide Antibiotics with Best-in-Class Potential
Can we make a better vancomycin?
- 2021 - 2023
- Nathaniel Martin
- TTW – NACTAR programme
This proposal concerns a novel class of guanidino lipoglycopeptide antibiotics recently discovered by researchers at Leiden University. These new antibiotics demonstrate dramatically enhanced activities compared to vancomycin, the most frequently prescribed glycopeptide. Notably, these new antibiotics are highly active against drug resistant bacteria including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant enterococci (VRE).